文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳腺癌细胞中程序性死亡蛋白-1-曲妥珠单抗耐药调控网络的生物信息学分析

Bioinformatics Analysis of Programmed Death-1-Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells.

作者信息

Hermawan Adam, Putri Herwandhani

机构信息

Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia.

Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2025 Jan 1;26(1):279-292. doi: 10.31557/APJCP.2025.26.1.279.


DOI:10.31557/APJCP.2025.26.1.279
PMID:39874011
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12082418/
Abstract

OBJECTIVE: Programmed cell death-1 (PD-1, encoded by PDCD1) regulatory network participates in glioblastoma multiforme development. However, such a network in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains to be determined. Accordingly, this study was aimed to explore the PD-1 regulatory network responsible for the resistance of breast cancer cells to trastuzumab through a bioinformatics approach. METHODS: The study used data mining tools like cBioportal and OMIM to identify genes involved in the programmed cell death-1-trastuzumab resistance regulatory network. The network was further examined using various tools like WebGestalt, DAVID, STRING, Cytoscape, CytoHubba, GEPIA, TNMPlot, and ROCPlot. RESULTS: The PDCD1 regulatory network in trastuzumab-resistant HER2+ breast cancer is linked to Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), interleukin (IL)-10, protein tyrosine phosphatase receptor type C (PTPRC), and FCGR2B. These factors have a significant prognostic power in pathological complete response in breast cancer patients treated with trastuzumab. Infiltration of B cells, CD8+ cells, CD4+ cells, neutrophils, dendritic cells, macrophages, and regulatory T cells is directly correlated with PTR expression. CONCLUSION: The study identified four genes (CTLA4, IL10, PTPRC, and FCGR2B) that are linked to the regulatory network of PD-1 in trastuzumab-resistant HER2+ breast cancer cells. Further research is needed to develop the therapeutic target against trastuzumab resistance in HER2+ breast cancer.

摘要

目的:程序性细胞死亡蛋白1(PD-1,由PDCD1编码)调控网络参与多形性胶质母细胞瘤的发展。然而,曲妥珠单抗耐药的人表皮生长因子受体2阳性(HER2+)乳腺癌中的此类网络仍有待确定。因此,本研究旨在通过生物信息学方法探索负责乳腺癌细胞对曲妥珠单抗耐药的PD-1调控网络。 方法:本研究使用cBioportal和OMIM等数据挖掘工具来识别参与程序性细胞死亡蛋白1-曲妥珠单抗耐药调控网络的基因。使用WebGestalt、DAVID、STRING、Cytoscape、CytoHubba、GEPIA、TNMPlot和ROCPlot等各种工具对该网络进行进一步研究。 结果:曲妥珠单抗耐药的HER2+乳腺癌中的PDCD1调控网络与细胞毒性T淋巴细胞相关抗原4(CTLA-4)、白细胞介素(IL)-10、蛋白酪氨酸磷酸酶受体C型(PTPRC)和Fc段γ受体IIb(FCGR2B)相关。这些因素对接受曲妥珠单抗治疗的乳腺癌患者的病理完全缓解具有显著的预后预测能力。B细胞、CD8+细胞、CD4+细胞、中性粒细胞、树突状细胞、巨噬细胞和调节性T细胞的浸润与PTR表达直接相关。 结论:本研究确定了四个与曲妥珠单抗耐药的HER2+乳腺癌细胞中PD-1调控网络相关的基因(CTLA4、IL10、PTPRC和FCGR2B)。需要进一步研究以开发针对HER2+乳腺癌中曲妥珠单抗耐药的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/d192480e758c/APJCP-26-279-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/49399518302b/APJCP-26-279-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/333c3185ce8e/APJCP-26-279-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/4e39881fe710/APJCP-26-279-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/3a7eba2ccdb8/APJCP-26-279-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/0dcd8c456af7/APJCP-26-279-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/d192480e758c/APJCP-26-279-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/49399518302b/APJCP-26-279-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/333c3185ce8e/APJCP-26-279-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/4e39881fe710/APJCP-26-279-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/3a7eba2ccdb8/APJCP-26-279-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/0dcd8c456af7/APJCP-26-279-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/12082418/d192480e758c/APJCP-26-279-g006.jpg

相似文献

[1]
Bioinformatics Analysis of Programmed Death-1-Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells.

Asian Pac J Cancer Prev. 2025-1-1

[2]
Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.

Asian Pac J Cancer Prev. 2024-11-1

[3]
Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types.

Sci Rep. 2025-7-2

[4]
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.

Future Oncol. 2024-12

[5]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[6]
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.

BMJ Open. 2017-3-13

[7]
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.

Int J Clin Pharmacol Ther. 2018-2

[8]
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Health Technol Assess. 2011

[9]
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).

J Clin Oncol. 2025-2-10

[10]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

本文引用的文献

[1]
Bioinformatics analysis of microenvironment-related genes associated with radioresistance in glioblastoma.

Transl Cancer Res. 2020-12

[2]
Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.

Front Immunol. 2021

[3]
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

Int J Mol Sci. 2021-12-27

[4]
Role of Fcγ receptors in HER2-targeted breast cancer therapy.

J Immunother Cancer. 2022-1

[5]
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

Nat Cancer. 2021-4

[6]
CCR2 and PTPRC are regulators of tumor microenvironment and potential prognostic biomarkers of lung adenocarcinoma.

Ann Transl Med. 2021-9

[7]
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.

Comput Struct Biotechnol J. 2021-7-18

[8]
Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.

Theranostics. 2021

[9]
Regulatory Network of PD1 Signaling Is Associated with Prognosis in Glioblastoma Multiforme.

Cancer Res. 2021-11-1

[10]
Interleukin-10: A double-edged sword in breast cancer.

Tzu Chi Med J. 2021-2-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索